Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population - Concepedia

Concepedia

Publication | Open Access

Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population

DOI Full Paper Access

25

Citations

32

References

2021

Year

Jeffrey S. Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Yun Jung, Patrick Lefèbvre, Veronica Ashton

Current Medical Research and Opinion

Abstract

These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.

References

	Year	Citations

Page 1